Report of the Relapsed/Refractory Cohort of SWOG S0919: A Phase 2 Study of Idarubicin and Cytarabine in Combination with Pravastatin for Acute Myelogenous Leukemia (AML)

Inhibition of cholesterol synthesis and uptake sensitizes acute myeloid leukemia (AML) blasts to chemotherapy. A Phase 2 study of high dose pravastatin given in combination with idarubicin and cytarabine demonstrated an impressive response rate [75% complete remission (CR), CR with incomplete count...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Leuk Res
Prif Awduron: Advani, Anjali S., Li, Hongli, Michaelis, Laura C., Medeiros, Bruno C., Liedtke, Michaela, List, Alan F., O’Dwyer, Kristen, Othus, Megan, Erba, Harry P., Appelbaum, Frederick R.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2018
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6574123/
https://ncbi.nlm.nih.gov/pubmed/29407182
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2018.01.021
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg